688131 Stock Overview
Researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 688131 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Shanghai Haoyuan Chemexpress Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥41.10 |
| 52 Week High | CN¥48.39 |
| 52 Week Low | CN¥17.86 |
| Beta | 0.59 |
| 1 Month Change | -13.27% |
| 3 Month Change | 13.13% |
| 1 Year Change | 48.57% |
| 3 Year Change | -37.07% |
| 5 Year Change | n/a |
| Change since IPO | -64.02% |
Recent News & Updates
Shanghai Haoyuan Chemexpress Co., Ltd. (SHSE:688131) Not Flying Under The Radar
Feb 11
Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) Shares Climb 36% But Its Business Is Yet to Catch Up
Nov 06Recent updates
Shanghai Haoyuan Chemexpress Co., Ltd. (SHSE:688131) Not Flying Under The Radar
Feb 11Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) Shares Climb 36% But Its Business Is Yet to Catch Up
Nov 06Does Shanghai Haoyuan Chemexpress (SHSE:688131) Have A Healthy Balance Sheet?
Oct 16Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) 25% Jump Shows Its Popularity With Investors
Sep 19Investors Appear Satisfied With Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) Prospects
Jul 13Shanghai Haoyuan Chemexpress (SHSE:688131) Has A Somewhat Strained Balance Sheet
Jun 13Earnings Troubles May Signal Larger Issues for Shanghai Haoyuan Chemexpress (SHSE:688131) Shareholders
May 06After Leaping 27% Shanghai Haoyuan Chemexpress Co., Ltd. (SHSE:688131) Shares Are Not Flying Under The Radar
Mar 20Shareholder Returns
| 688131 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -0.4% | -0.4% | -2.1% |
| 1Y | 48.6% | 22.8% | 11.6% |
Return vs Industry: 688131 exceeded the CN Life Sciences industry which returned 22.8% over the past year.
Return vs Market: 688131 exceeded the CN Market which returned 11.6% over the past year.
Price Volatility
| 688131 volatility | |
|---|---|
| 688131 Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 3.4% |
Stable Share Price: 688131 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688131's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 3,437 | Baofu Zheng | www.chemexpress.cn |
Shanghai Haoyuan Chemexpress Co., Ltd. researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs. It offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.
Shanghai Haoyuan Chemexpress Co., Ltd. Fundamentals Summary
| 688131 fundamental statistics | |
|---|---|
| Market cap | CN¥8.67b |
| Earnings (TTM) | CN¥204.98m |
| Revenue (TTM) | CN¥2.26b |
42.3x
P/E Ratio3.8x
P/S RatioIs 688131 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688131 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.26b |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥2.26b |
| Other Expenses | CN¥2.05b |
| Earnings | CN¥204.98m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 0.97 |
| Gross Margin | 100.00% |
| Net Profit Margin | 9.08% |
| Debt/Equity Ratio | 49.1% |
How did 688131 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield20%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 23:00 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Haoyuan Chemexpress Co., Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |
| Mingrui Wang | Everbright Securities Co. Ltd. |